NCT05455502View on ClinicalTrials.gov

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

July 13, 2022

Primary Completion Date

September 17, 2022

Study Completion Date

September 17, 2022

Conditions

Pain

Interventions

DRUG

VX-548

Tablet for oral administration.

Trial Locations (1)

84124

ICON Salt Lake City, Salt Lake City

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY